| Project/Area Number |
21659338
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
TAKANO Shingo 筑波大学, 医学医療系, 准教授 (50292553)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAI Yasunobu 筑波大学, 医学医療系, 講師 (40535069)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,270,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2009: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | 膠芽腫 / 血管新生 / 腫瘍内皮細胞 / ケモカイン / 抵抗性 / 腫瘍微小環境 / 脳・硬膜動静脈奇形 / レーザーマイクロダイセクション / 腫瘍ニッチ / 脳動静脈奇形 |
|---|
| Research Abstract |
Glomeruloid vessel (GV) is a hallmark of glioblastoma vasculature. The role of GV was investigated with genetic alteration and immunohistochemistry using human glioblastoma frozen section. Endoglin, that is related to endothelial cell migration, was up-regulated in GV compared to small tumor vessels and tumor cells. Endoglin was localized in endothelial cells with smooth muscle cell actin and co-localized with phospholylated VEGFR2 (marker of VEGF antibody action) and CD133 (stem cell marker). Targeting endoglin has a possibility of a effective anti-angiogenic therapy damaging endothelial stem cell in glioblastoma.
|
